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art I: Gender Differences in Traditional and Novel Risk Factors,
ymptom Evaluation, and Gender-Optimized Diagnostic Strategies
eslee J. Shaw, PHD,* C. Noel Bairey Merz, MD,* Carl J. Pepine, MD,§ Steven E. Reis, MD,†
era Bittner, MD,** Sheryl F. Kelsey, PHD,‡ Marian Olson, MS,‡ B. Delia Johnson, PHD,‡
unil Mankad, MD, Barry L. Sharaf, MD,¶ William J. Rogers, MD,** Timothy R. Wessel, MD,§
hristopher B. Arant, MD,§ Gerald M. Pohost, MD,†† Amir Lerman, MD,‡‡
rshed A. Quyyumi, MD,§§ George Sopko, MD, for the WISE Investigators
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Despite a dramatic decline in mortality over the past three decades, coronary heart disease is
the leading cause of death and disability in the U.S. Importantly, recent advances in the field
of cardiovascular medicine have not led to significant declines in case fatality rates for women
when compared to the dramatic declines realized for men. The current review highlights
gender-specific issues in ischemic heart disease presentation, evaluation, and outcomes with
a special focus on the results published from the National Institutes of Health-National
Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation
(WISE) study. We will present recent evidence on traditional and novel risk markers (e.g.,
high sensitivity C-reactive protein) as well as gender-specific differences in symptoms and
diagnostic approaches. An overview of currently available diagnostic test evidence (including
exercise electrocardiography and stress echocardiography and single-photon emission com-
puted tomographic imaging) in symptomatic women will be presented as well as data using
innovative imaging techniques such as magnetic resonance subendocardial perfusion, and
spectroscopic imaging will also be discussed. (J Am Coll Cardiol 2006;47:4S–20S) © 2006
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.072by the American College of Cardiology Foundation
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Ischemic heart disease (IHD) remains the leading killer in
he U.S. and is the dominant contributor to the nation’s
orbidity and healthcare expenditures (1–3). While ad-
ances in the treatment of IHD have reduced case fatality
ates, subsequent heart disease survivors contribute to in-
reasing disease prevalence as a result of a growing popula-
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004, accepted January 4, 2005.ion of post-myocardial infarction, post-revascularization,
nd heart failure survivors that require substantive ongoing
ealthcare (4,5). Rising rates of cigarette smoking, physical
nactivity, obesity, hypertension, and the metabolic syn-
rome also contribute to the rising IHD incidence rates
mong younger women and men (5). While it seemed clear
n prior decades that we were “winning the war” on IHD,
he recent U.S. national trend data reveal a continuing, yet
larming, growth in the IHD epidemic that our overbur-
ened healthcare system is poorly equipped to handle
6–21).
For the sizeable proportion of women presenting for
oronary artery disease (CAD) evaluation, our traditional
isease management approaches that focus on detection of a
ritical stenosis often fail to identify those women critically
t-risk. More than a quarter of a million women die each
ear in the U.S. from IHD and its related conditions, and
urrent projections indicate that this number will continue
o rise with our aging population (1,2,5). Recent estimates
rom the Centers for Disease Control (CDC) reveal that
8% of all deaths in women are related to coronary heart
isease as compared with 22% resulting from cancer (5).
ndeed, since 1984, more women than men have died
nnually from IHD (2), refuting the notion that this is a
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woman’s affliction” (Fig. 1).
Notably, the dominance of disease attributable to women
s not simply due to aged women’s longevity as compared
ith men. Ischemic heart disease is the leading killer of
omen at all ages with annual mortality rates that affect
ore women under the ages of 35, 45, and 55 years than
reast cancer (2,5,22). Recent data from the CDC on
29,000 heart disease deaths reported in the U.S. noted that
udden death rates increased significantly from 38% in 1989
o 47% in 1999 and that women were more likely to die of
cardiac arrest before hospital arrival (52%) as contrasted
ith 42% for men. Although the total number of sudden
ardiac deaths is higher in men (23), this latter statistic of an
ncreasing pre-hospital sudden death rate in women is
oteworthy as it represents a significant change from prior
ecades (5,23,24).
The evaluation of IHD in women presents a unique and
ometimes difficult challenge for clinicians, due to their
igure 1. Cumulative % change in coronary heart disease mortality in black
Abbreviations and Acronyms
CAD  coronary artery disease
CDC  Centers for Disease Control
CI  confidence interval
DASI  Duke Activity Status Index
FRS  Framingham risk score
HDL  high-density lipoprotein
hsCRP  high sensitivity C-reactive protein
IHD  ischemic heart disease
LDL  low-density lipoprotein
METs  metabolic equivalents
MR  magnetic resonance
PCr/ATP  phosphocreatine/adenosine triphosphate
SPECT  single-photon emission computed
tomography
WISE  Women’s Ischemia Syndrome Evaluationpon recent estimates, there has been greater declines in coronary heart disease
enjamin EJ, et al. (20).reater symptom burden, higher rate of functional disability,
nd a lower prevalence of obstructive CAD by coronary
ngiography as compared to men. Notably, women with
HD have more adverse outcomes as compared with men
2,25,26) despite the repeatedly documented lower angio-
raphic disease burden and more often preserved left ven-
ricular function as compared to men (27).
The compendium of coronary heart disease data indicate
hat current research and strategy development must focus
n gender-specific issues in order to address the societal
urden and costs related to these demographic shifts in
HD that place women in the majority of those impacted.
his significant burden of the disease in women places
nique diagnostic, treatment, and financial encumbrances
n our society that are only further intensified by a lack of
ublic awareness about the disease on the part of patients
nd clinicians alike. This societal burden of the disease is, in
art, related to our poor understanding of gender-specific
athophysiologic differences in the presentation and prog-
osis of IHD and the paucity of diagnostic and treatment
uidelines tailored to phenotypic differences in women.
Our understanding of gender-specific differences in the
nitial presentation, pathophysiology, treatment effective-
ess, resource utilization patterns, and clinical outcomes
ave changed dramatically over the past decade (8,9,11–
3,28). Historically, research in the area of IHD has
onsistently reported that CAD is manifested earlier in the
ives of men, with much of the prior research focusing
xclusively on men and/or disproportionately enrolling male
atients. The more frequent evaluation of men has pro-
oted a perception that IHD was a “man’s disease,” and the
nsuing knowledge gap on the part of physicians and
atients alike created inequities in healthcare access and
rocesses of care that resulted in suboptimal care for at-risk
omen (1–26,29–35). Inequities in access are further exac-
hite women as compared with men in the U.S. from 1979 to 1998. Basedand w
mortality in men as compared with black or white women. Adapted from
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36–38). It is increasingly appreciated that socioeconomic
isparities and psychosocial issues in varying ethnic female
ubsets compound the challenges in assessing at-risk women
esulting in underutilization, underdiagnosis, and under-
reatment patterns of care (1–3,6,12,16,17,39–41).
Our current understanding and treatment of IHD patho-
hysiology in women is based on “critical stenosis” diagnos-
ic approaches. New findings support the concept of a
ultifactorial model where sex hormones interact with
raditional and conditional risk markers leading to an
ncrease in the functional expression of atherosclerotic
laque deposition or vascular or metabolic alterations result-
ng in worsening outcomes for women (1). The current
eview provides a synopsis of available evidence on gender-
ased differences in IHD and outlines important next steps
oward enhancing detection aimed at improving outcomes
or women. Part I of the review focuses on developing an
nderstanding of gender-specific differences in traditional
nd novel risk factors as well as gender differences in the
iagnosis of CAD (42–47).
ENDER-SPECIFIC DIFFERENCES
N IHD PREVALENCE AND RISK FACTORS
espite being the leading killer of women at all ages, the
revalence of obstructive CAD in women is relatively low
efore menopause (average age 51 years) (4,48–52), only
pproaching equal prevalence rates for men and women in
heir seventh decade of life (2,5,52,53). In general, compa-
able incidence rates are achieved for women who are 10
ears older, such that the CAD rates of 55-year-old men are
imilar to that of 65-year-old women (4). The delayed onset
f the disease results in a relatively lower likelihood of
bstructive CAD for most of the women we evaluate
ncluding those in their fourth through seventh decades of
ife.
When risk factors are compiled in the form of global risk
cores (e.g., Framingham risk score [FRS], calculated by
umming point scores [or by adding risk equivalents] given
o age, blood pressure, cholesterol, diabetes, and cigarette
moking), 4%, 13%, and 47% of women ages 50 to 59, 60 to
9, and 70 to 79 years, respectively, are at intermediate-high
isk of coronary heart disease death or non-fatal myocardial
nfarction, respectively (54). For a 40-year-old woman, her
ifetime risk of CAD, as based upon the FRS, is 0% to 2.3%
or those with a low, intermediate, to high FRS as compared
o rates ranging up to 11.6% for 40-year-old men (55).
lthough a family history of premature CAD is missing
rom the Framingham risk equation, individuals with at
east one parent with premature CAD (onset age 55 years
n a father, 65 years in a mother) have a greater risk for
AD events with age-adjusted odds ratios of 2.6-fold (95%
onfidence interval [CI] 1.7 to 4.1) higher for men and
.3-fold (95% CI 1.3 to 4.3) higher for women (56). IThere is also substantial gender-related variability in the
revalence and outcome associated with traditional cardiac
isk factors (Table 1). That is, although overall rates of
ypertension and smoking are higher in men, elderly hy-
ertensive women and young female smokers are prominent
t-risk subsets (2,5,57,58). Cigarette smoking is noted to
ncrease inflammation, thrombosis, and oxidation of low-
ensity lipoprotein (LDL) cholesterol supporting the hy-
othesis that there is a dose-response relationship between
moking and increased oxidative stress as a potential link to
AD (59). However, for women smokers, coronary heart
isease mortality risk from cigarettes is equivalent to the risk
ssociated with weighing 42 kg more than her non-
moker counterpart (60).
Population studies have noted that total cholesterol mea-
urements are higher in men until the fifth decade of life
ut, beyond this age, women have greater values (57,58).
urthermore, gender differences in high-density lipoprotein
HDL) values diminish with advancing age. High-density
ipoprotein cholesterol values decline in men at the time of
uberty and are generally lower than those of women at all
ges. Women typically experience a relatively mild decline
n HDL cholesterol at the time of menopause (2,4,5). In a
omprehensive review of 25 population studies, Manolio et
l. (61) reported that HDL cholesterol inversely predicted
oronary heart disease in younger women and men as well as
lder (65 years) women. However, HDL cholesterol was
ot predictive of fatal coronary heart disease in older men
61). Thus, for all but HDL cholesterol, the relative risks for
able 1. A Comparison of Gender Differences in Traditional
ardiac Risk Factors Including Differences in Varying Age
hresholds, Mean Population, Prevalence, and Outcome
ifferences
Men Women
isk factor threshold values
Age threshold for 1 disease risk 45 yrs 55 yrs
Family history of premature
CHD
55 yrs 65 yrs
HDL cholesterol 50 mg/dl
opulation average values
Lipids
Total cholesterol 1 1 For women after
age 50 yrs
HDL cholesterol 1
revalence rates
Hypertension* 1
Smoking† 1
oronary disease or outcome risk
Triglycerides 1
Diabetes mellitus 1
Obesity (e.g., BMI 30 kg/m2)‡ 1 1
Central obesity (35 kg/m2*) 1
aps narrow: *in elderly, †women lag in declining rates of smoking and noted
ncreased prevalence of young female smokers; ‡obesity increasing in the last decade
uch that 25% of women are now obese with a body mass index (BMI) 30 kg/m2.
dditionally, women generally engage in less leisure-time physical activity and exhibit
greater functional decline in their postmenopausal years.
CHD  coronary heart disease; HDL  high-density lipoprotein.HD in women and men as related to total and LDL
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ubclasses, women do have less atherogenic subclass profiles
han men (62). Recent evidence from the Framingham
ffspring study, however, reported that women have a
wo-fold higher concentration of large HDL particles when
ompared with men (8 vs. 4 mmol/l) (62). Hypertriglycer-
demia is also a more potent independent risk factor for
HD in women as compared with men (4). A recent
eta-analysis of 17 studies (n  46,413 men and 10,864
omen) revealed that the coronary heart disease relative risk
or hypertriglyceridemia was elevated 32% in men and 76%
or women (63).
Although younger-aged diabetic women (i.e., 45 years)
ave an equally low prevalence of atherosclerosis (64),
umerous studies have reported a significantly higher car-
iovascular mortality for diabetic women as compared with
iabetic men (65–67). Notably, the age-adjusted prevalence
f cardiovascular disease is nearly two-fold higher in dia-
etic versus non-diabetic women (57), with the highest risk
eing reported in non-Hispanic blacks. Thus, it appears that
iabetes eliminates the “female advantage” of a predomi-
ately lower CAD prevalence and outcome risk that is
ealized for the majority of women (66). While some of the
ender-related differences in mortality for diabetic women
ppear to be related to older age, more frequent hyperten-
ion, hyperlipidemia, poor glycemic control, and higher
moking rates, much of the relatively greater risk for IHD
ssociated with diabetes in women remains unanswered
65,68).
As women progress through the approximately one-third
f their life in menopause, there appears to be a greater loss
n physical functioning when compared with their male
ounterparts (69). This greater loss in functional capabilities
ontributes to greater weight gain, insulin resistance, and
ypertension (70–72). Furthermore, a loss in ovarian estro-
en during menopause is associated with an androidal shape
nd deposition of abdominal fat, a body habitus profile that
s more often associated with an increased CAD risk in
omen (72). In women, body mass index is more closely
ssociated with computed-tomographic-determined an-
hropometric measurements of visceral adipose tissue (73).
ith an increasing prevalence of obesity in U.S. women
from 12.2% in 1991 to 20.8% in 2001), the accompanying
ising frequency of insulin resistance, dyslipidemia, diabetes,
nd hypertension will likely contribute to increasing rates of
HD (70–72,74). Some have posited that poor childhood
utrition and lower socioeconomic status may precipitate
nsulin resistance and obesity, thus increasing a woman’s
isk of CAD (75).
Recent evidence from the Women’s Ischemia Syndrome
valuation (WISE) study reported that overweight women
ere more likely than normal weight women to have CAD
isk factors. Interestingly, neither body mass index nor
bdominal obesity measures were significantly associated
ith obstructive CAD or adverse cardiovascular events afterdjusting for other risk factors (p  0.05 to 0.88) (76). ahus, it appears that the metabolic alterations associated
ith obesity are key factors in placing a woman at risk for
AD and cardiac events.
A clustering of risk factors is common in postmenopausal
omen, notably obesity, hypertension, and dyslipidemia
2,5,57,58,66,77–85), possibly related to gender-specific
etabolic differences exacerbated by hormonal imbalances.
he metabolic syndrome represents a clustering of risk
onditions including insulin resistance (with or without
lucose intolerance), dyslipidemia (elevated triglycerides,
mall LDL particles, or low HDL cholesterol), hyperten-
ion, and abdominal obesity. Recently, the National Cho-
esterol Education Program Adult Treatment Panel-III
implified the definition as that occurring in the presence of
hree or more of the following (for women): 1) waist
ircumference 35 inches; 2) fasting triglycerides 150
g/dl; 3) HDL cholesterol 50 mg/dl; 4) hypertension
systolic blood pressure 130 mm Hg, diastolic blood
ressure 85 mm Hg, or use of antihypertensive drug
herapy); or 5) a fasting glucose measurement 110 mg/dl
83,84). Recent evidence suggests that obesity itself is not an
ndependent predictor of disease but that the metabolic
yndrome is one link between obesity and cardiovascular
isease (86).
Women with the metabolic syndrome have an increased
revalence of subclinical disease, and they are at an inter-
ediate cardiovascular disease mortality risk when com-
ared to those with normal glucose levels or frank diabetes
85–90). In a recent report by Marroquin et al. (90), the
our-year relative risk of cardiac events was increased ap-
roximately two-fold for women in the WISE study with
he metabolic syndrome as compared to those with a normal
etabolic status (Fig. 2). Larger waist circumferences in
omen with the metabolic syndrome may play a role in
orsening cardiac risk factor profiles leading to an increased
isk of CAD. For example, women with larger waist
ircumference measurements walk on average 1,000 fewer
teps per day and are, thus, less active (91) minimizing the
eneficial effects of a healthier lifestyle on lipids, blood
ressure, and glucose measurements. Women with a history
f polycystic ovary syndrome have a greater frequency of
ultiple risk factors including central obesity, insulin resis-
ance, and a greater prevalence of the metabolic syndrome
nd diabetes, although studies linking this with an increase
n IHD are inconsistent (92).
Interestingly, there is a strong relationship between the
etabolic syndrome and depression, a relationship that may
e particularly relevant given the 70% higher prevalence of
epression in women (93). In the WISE study, approxi-
ately one in four women reported prior treatment for
epressive symptoms (39). Lett et al. (94) recently put forth
everal possible mechanisms for the link between depression
nd the metabolic syndrome including poor treatment
dherence, lifestyle factors, traditional risk factors, platelet
ctivation, and inflammation but also dysfunction of the
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enal axis.
EX HORMONES AS RISK FACTORS FOR IHD
n the premenopausal woman with normal ovulation, en-
ogenous sex hormones including estrogen are hypothesized
s the primary reason for their low incidence of IHD as
ompared with age-matched men. During menopause, a
oman’s estrogen levels are approximately one-tenth of that
uring her premenopausal years (95). Estradiol is the
redominant source of estrogen in the premenopausal years
hile estrone, produced by peripheral conversion of andro-
ens in the adipose tissue, is the main source during a
oman’s postmenopausal years. Thus, not only is the overall
evel of estrogen lower postmenopausally but the predomi-
ant estrogen type varies from a woman’s pre- to postmeno-
ausal years. It is reasonable, therefore, to hypothesize that
he endogenous estrogen type might provide relative pro-
ection from IHD premenopausally because of the many
nimal studies that have demonstrated the antiatheroscle-
otic effects of estrogen (95–98). Additionally, basic science
ork shows that estrogen reduces cellular hypertrophy,
nhances vessel wall elasticity, and has antioxidative and
igure 2. From the National Institutes of Health-National Heart, Lung,
vent-free survival by metabolic status was recently reported in women. Th
isk for major adverse cardiac events (MACE) (death, non-fatal myocardia
t al. (90).nti-inflammatory properties (95–98). pThe WISE study results suggest that endogenous estro-
en deficiency in young women may be a potent risk factor
or IHD (99). We observed in premenopausal women that a
tress-induced central disruption in ovulatory cycling with
esulting hypoestrogenemia was associated with a 7.4-fold
95% CI 1.7 to 33.3) increased risk of obstructive CAD
measured at coronary angiography) in women with suspected
schemia (99). In this report, hypoestrogenemia of hypotha-
amic origin (defined as measurements of estradiol 184
mol/l [50 pg/ml], follicle stimulating hormone10 IU/l, and
uteinizing hormone10 IU/l) was the most powerful predic-
or of angiographic CAD. Further work in the WISE study
as also documented a protective effect of prior oral contra-
eptive use for later-onset postmenopausal atherosclerosis
100). The WISE study findings, supported by other publica-
ions, suggest that premenopausal estrogen deficiency due to a
entral disruption of ovarian function may be a potent risk
actor for IHD. Premenopausal estrogen deficiency could
xplain the more adverse prognosis experienced by younger
ost-myocardial infarction women when compared to age-
atched men (26,27). And, finally, although this discussion
as focused on estrogen, androgens have been shown to express
therosclerotic-related genes in men but not in women, per-
aps contributing to the gender-related differences in CAD
Blood Institute Women’s Ischemia Syndrome Evaluation (WISE) study,
sults reveal that women with the metabolic syndrome are at intermediate
ction, stroke, or congestive heart failure). Reprinted from Marroquin OC,and
ese rerevalence (101).
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review of evidence reveals that the compilation of tradi-
ional risk factors underestimate risk in women (54–
5,102–104). This pattern of underrecognition in women
as prompted additional research to assess the value of novel
isk markers (e.g., inflammatory markers, retinal artery
arrowing, coronary calcification) that may provide im-
roved accuracy for the detection of CAD in women
54,55,102–104). Accordingly, evaluation of the role of
ovel risk markers, such as inflammation (e.g., high sensi-
ivity C-reactive protein [hsCRP]) (105–107), suggests an
mproved predictive accuracy above and beyond traditional
isk factors in estimating cardiovascular disease risk in
omen. Recently, a number of reports have introduced a
ariety of laboratory and imaging risk markers that uniquely
nd/or differentially predict cardiovascular disease risk in
omen (104–112).
Evidence to support the utility of novel risk markers are
he data revealing a lack of correlation between novel and
raditional risk factors, such as a poor correlation between
sCRP and LDL cholesterol measurements (113). Addi-
ionally, recent reports have also noted that hsCRP mea-
urements provide added prognostic value (over and above
raditional risk factors) in estimating important cardiovas-
ular events in large epidemiologic cohorts of women
104,106,107,112,113). For example, in the Women’s
ealth study, a prospective cohort of approximately 30,000
iddle-aged, predominantly postmenopausal apparently
ealthy women, the relative risk of future vascular events
ncreased as the level of hsCRP went from low-normal to
igh-normal (106). This was true for all cardiovascular
vents as well as for the specific combined end point of
yocardial infarction or stroke.
High sensitivity C-reactive protein also acts synergisti-
ally with other risk factors in estimating prognosis where
he presence of both LDL cholesterol and being a current
moker raised the relative risk of cardiovascular death and
ther events in women (106,107,114,115). Of note, hsCRP
as also been related to other markers of cardiovascular risk
ncluding the metabolic syndrome, type 2 diabetes, and
ongestive heart failure (114–116). For women with the
etabolic syndrome and high levels of hsCRP, their risk of
ardiovascular events was similar to that of diabetic women
89,90). This illustrates a potentially productive approach
or improving risk assessment in women such that, although
omen are generally at lower risk when compared with
en, the combination (i.e., clustering) of risk markers acts
dditively and/or multiplicatively to increase risk and there-
ore improve risk assessment for female cohorts.
Other inflammatory markers, like fibrinogen, have been
valuated; however, it appears that hsCRP and interleukin-6,
oth acute phase reactants, may play a role in risk evaluation
ue to their ease of evaluation, standardization of methods,
epeatability, and low cost (116). wThe predictive value of novel risk markers may provide us
ith additional insight into gender-specific differences in
he pathophysiology of IHD; hsCRP measurements corre-
ate with signs and symptoms of myocardial ischemia and
ay be related to the pathogenesis of angina in women, in
articular for those with non-obstructive CAD (117). In-
erestingly, data from the Third National Health and
utrition Examination Survey demonstrate that women, in
eneral, have higher mean C-reactive protein values com-
ared with men, with the difference becoming apparent at
he time of puberty (118). A relatively high C-reactive
rotein 1 mg/dl was observed in 13% of women as
ompared with only 6% of men in this population survey
118); hsCRP measurements not only vary by gender but
lso by ethnicity. From the Women’s Health study, median
-reactive protein levels were, on average, significantly
igher among black women (2.96 mg/l) than among white
2.02 mg/l), Hispanic (2.06 mg/l), or Asian (1.12 mg/l)
omen (119).
Recent data support hypotheses of an autoimmune pre-
ursor for atherosclerotic disease in women. Notably,
ender-specific differences in C-reactive protein, as an
nflammatory marker, are consistent with the observed 2- to
0-fold greater frequency of inflammatory-mediated auto-
mmune diseases, such as rheumatoid arthritis, systemic
upus erythematosus, thyroiditis, etc. in women as compared
o men (120). This work suggests that inflammation may
lay a gender-specific role in atherosclerotic disease for
omen, although this reasoning is currently speculative
121). In a recent matched case-control study of 394
atients (90% women), evidence of atherosclerotic plaque
as measured by carotid ultrasonography) was present nearly
ve times more often in those with systemic lupus erythem-
tosus when compared to age- and gender-matched healthy
ontrols (122). In another matched case-control series of
atients with systemic lupus erythematosus (85% women
f 134 patients), the prevalence of coronary calcification, a
easure of atherosclerotic plaque burden, increased dramat-
cally after age 50 years (123). Thus, it may be a combina-
ion of aging and/or the exposure duration of the autoim-
une disease on the cardiovasculature that may impact on
he atherosclerotic plaque process. We await further work
n the relationship between atherosclerotic disease and
heumatoid arthritis, a more common condition in women,
o further support this hypothesis of an autoimmune pre-
ursor for cardiovascular disease.
Anemia has also recently been linked to worsening out-
omes in women. Anemia in patients presenting with acute
yocardial infarction or heart failure has frequently been
ssociated with adverse outcomes. The WISE study group
ecently reported on the prognostic significance of hemoglobin
alues in women with suspected ischemia. In this report,
nemic women had a higher risk of all-cause death (10% vs.
%; p  0.02) and major adverse cardiovascular outcomes
26% vs. 16%; p  0.01) when compared with non-anemic
omen. Additionally, in a risk-adjusted Cox model, decreasing
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utcomes (hazard ratio  1.20, p  0.002). Anemic women
lso had a shorter survival time free of adverse outcomes (p 
.001). These findings extend previous reports noting an
nverse relationship between lower hemoglobin values and
igher risk of adverse cardiovascular outcomes to those women
ith chest pain symptoms (124).
SSESSMENT OF MYOCARDIAL ISCHEMIA
ND OBSTRUCTIVE CORONARY DISEASE IN WOMEN
ymptom assessment. The evaluation of chest pain symp-
oms in women has been hampered by attempts to apply a
typical” angina definition derived from predominantly male
opulations to female cohorts, as there are substantial
ifferences between women and men in the type, frequency,
nd quality of symptoms noted during their presentation
125). For women, prodromal symptoms are often unusual
ncluding fatigue, sleep disturbance, and shortness of breath.
espite the reported gender differences, typical symptoms
re significantly associated with acute coronary syndromes
n women (126). In a recent report, there were no observed
ender differences in the accuracy of typical symptoms,
efined as chest pain or discomfort, dyspnea, diaphoresis,
nd arm or shoulder pain, in diagnosing acute coronary
yndromes (126). Of these features, chest pain or discomfort
nd diaphoresis were characteristics mostly associated with
cute coronary syndromes in women. Additionally, women,
n general, report more acute than prodromal symptoms,
nd up to half of women presenting with an acute myocar-
ial infarction report no prior chest pain symptoms (127). In
ome reports, women present less often than men with
xertional chest pain symptoms that may be defined as
typical” angina (2,49,50). However, women present more
requently than men for the evaluation of and are hospital-
zed more often for chest pain (4.0 million visits for women
s. 2.4 million visits for men) (2).
Thus, it appears from reviewing this evidence that the
ualifying symptom characteristic that discerns women and
en is an exertional component to the defining of typical
ngina. It does appear that as defined by the Yale group that
ypical angina that includes chest pain or discomfort, dys-
nea, diaphoresis, and arm or shoulder pain is accurate at
etection of unstable angina but that, in many reports, the
nclusion of exertional components often renders dramatic
ender-related differences in symptom predictive accuracy.
There does appear to be an interaction effect of symptom
resentation with age, in that older women often present
imilarly to men. This would include the fact that older
omen have more frequent typical angina. However,
omen 65 years are also 50% more likely than younger
en to be discharged with a diagnosis of unstable angina.
here is no gender difference in the rate of acute coronary
yndromes in older patients hospitalized for chest pain
yndromes (age interaction p 0.0001) (128). Additionally,
ounger women are also less likely to present with ST- (egment elevation, a factor that may protract their time to
iagnosis, the ensuing intensity of management, and result
n worsening outcomes.
When evaluated for symptoms suggestive of myocardial
schemia, women have lower rates of obstructive CAD at
ngiography (Fig. 3) (48–50,104). This lower CAD likeli-
ood by gender was initially suggested, by Diamond and
orrester (129), nearly two decades ago. From their early
ork, women with typical or atypical chest pain symptoms
ave calculated obstructive CAD probabilities substantially
ess than that of men. For example, typical exertional angina
n a 55-year-old man has a probability of obstructive CAD
f approximately 90% as compared with a wide range from
5% to 90% for a 55-year-old woman. This observation that
hest pain symptoms are less accurate and less precise
redictors of obstructive CAD in women continues to be
oted in contemporary data series (130,131).
In particular for diabetic patients, symptoms are generally
ot as effective guides to CAD risk as compared with objective
vidence of ischemia (132). In part, a woman’s description of
ymptoms may be a guiding force in determining the likeli-
ood of CAD (133). For patients with stable, intermittent
hest pain, their description of pain is the most important
redictor of CAD and may be a factor contributing to less
ntensive management for female patients (133). Today, how-
ver, we face several critically important questions for evaluat-
ng symptoms in women: can current symptom evaluation
ools be improved for more accurate detection of obstructive
AD in women? Do symptom differences suggest a gender-
pecific pathophysiology such that gender-specific new tools
hould be developed for assessment of IHD in women (134–
37)? However, as yet, evidence is not available to definitively
nswer these questions.
A majority of women without obstructive CAD at
oronary angiography continue to have symptoms that
ontribute to a poor quality of life and consumption of large
mounts of health care resources due to repeated evaluations
nd hospitalizations (39,104,138–140). In many cases, phy-
icians rely upon cardiac imaging to differentiate cardiac
rom non-cardiac symptoms in women (141). However, this
pproach leaves unanswered the question of how to detect
nd manage myocardial ischemia in the absence of signifi-
ant obstructive CAD.
xercise electrocardiographic (ECG) evaluation. The
xercise ECG is the most frequently performed diagnostic
est. Its use and indications for women are limited to those
ith a relatively normal 12-lead ECG and capabilities of
erforming moderate-to-high levels of exercise. These pre-
equisites are increasingly found in only a minority of
omen referred for IHD assessment (142). The exercise
CG, using a threshold for abnormality of 1.0 mm of
T-segment depression, has a lower diagnostic accuracy
sensitivity and specificity for significant coronary artery
bstruction 60% to 70%) in women as compared to men
with diagnostic sensitivity and specificity measures 80%)
143–146) (Table 2).
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February 7, 2006:4S–20S Gender Differences, Symptom Evaluation, and Diagnostic StrategiesThis diminished accuracy in women is related, in part, to
heir lower CAD prevalence as well as greater comorbidity
nd functional impairment that preclude women from
chieving maximal levels of exercise when compared with
generally) more active men (Table 3). Women undergoing
xercise testing are often incapable of performing 5
etabolic equivalents (METs) of treadmill exercise leading
o inadequate heart rate responses (147). In sedentary
omen, an early hyperexaggerated heart rate response,
xcessive dyspnea, and premature fatigue can be seen within
he first few minutes of exercise, in particular with the
ggressive Bruce protocol where stage I requires 4.7 METs
f work. Women performing submaximal levels of exercise
ith no inducible ischemia typically remain without diag-
ostic confirmation and explanation for their symptoms,
igure 3. From the National Heart, Lung, and Blood Institute Women’s
rtery disease (CAD) as compared with observed coronary disease prevalen
hese results note that probability estimates based upon data series of severa
pon a comparison of a contemporary series of women referred to coronar
typical angina. Solid bars  WISE prevalence; open bars  Diamond
able 2. A Compilation of Published Meta-Analyses on the Diag
chocardiography, and Stress SPECT Imaging in Women
Exercise Electrocardiography
Author, Year (Ref.) Sensitivity Specificity
leischmann et al., 1998 (143) — —
wok et al., 1999 (146) 61% 70%
eattie et al., 2003 (143) — —
verage 61% 70%PECT  single-photon emission computed tomography.hus raising anxiety and depression about the basis for their
hest pain (39).
Other reasons posited for a diminished accuracy of the ECG
n women include a lower QRS voltage and hormonal factors.
digoxin-like effect of endogenous estrogen can possibly
romote higher false positive rates in premenopausal women.
ormone replacement therapy, with its ensuing vasodilatory
roperties, may result in false negative test results (148–158)
Table 3). For the premenopausal woman, chest pain and the
nducibility of ST-segment abnormalities can vary by the
enstrual cycle with lower mid-cycle estradiol levels being
ssociated with a greater frequency, intensity, and severity of
CG-based ischemia (148–159). All of these reasons may play
role in the diminished accuracy of chest pain and ST-
egment changes in women (43).
mia Syndrome Evaluation (WISE), the Diamond probability of coronary
symptomatic women ages 35 to 45, 46 to 55, 56 to 65, and 66 to 75 years.
des ago overestimate the likelihood of coronary disease in women; as based
iography. Atyp Ang  atypical angina; Nonang  non-angina; Typ Ang
ability.
ic Accuracy of Exercise Electrocardiography, Stress
Stress Echocardiography Stress SPECT
Sensitivity Specificity Sensitivity Specificity
85% 77% 87% 64%
86% 79% 78% 64%
81% 73% 77% 69%
84% 76% 81% 66%Ische
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Gender Differences, Symptom Evaluation, and Diagnostic Strategies February 7, 2006:4S–20SThese data reveal that relying on the exercise ECG alone
or IHD detection may be imprecise and more precarious in
omen than in men. However, exercise stress test risk scores
e.g., Duke treadmill score) have been shown to improve
rognostication in women but, of all the factors noted
uring testing, the strongest predictive parameter from the
readmill test is exercise duration (43,159–163). Of note,
omen have generally worse functional capacity, engage less
ften in physical exercise programs, and have more func-
ional decline during their menopausal years as compared to
ge-matched men (69). Women who achieve5 METs are
t increased risk of cardiac events (Fig. 4) (142,147,161–
63). For women, information as to their capabilities when
erforming activities of daily living may be a useful guide to
pproximate peak MET levels (147). Specifically, routine
ousehold activities require about 4 METs of work.
Recently, the 12-item Duke Activity Status Index (DASI)
uestionnaire has been shown to risk stratify women
76,147,164–166). Using self-reported activities of daily living,
omen achieving 4.7 METs of work had a 3.7-fold in-
reased risk of death or non-fatal myocardial infarction when
ompared to those women reporting higher functional abilities
147). From this recent report by Shaw et al. (147), two-thirds
f the cardiac events in the WISE women occurred in those
ith an estimated capacity of 4.7 DASI METs. In the
ISE study, women with evidence of lower DASI scores were
lso significantly more likely to have risk factors and
bstructive CAD (44% vs. 26%; p  0.001) and each
-MET increase in the DASI score was independently
ssociated with an 8% (hazard ratio, 0.92; 95% CI 0.85 to
.99; p  0.02) decrease in risk of major adverse cardiovas-
ular events during follow-up (76).
Peak and recovery heart rate measures also improve risk
ssessment and diagnostic accuracy for IHD in women (167–
d symptomatic (n 8,214) women as synthesized from published reports.igure 4. Prognostic value of functional capacity in asymptomatic (n 8,715) anable 3. Factors Affecting the Accuracy of Diagnostic Testing
n Women
) Menopausal status
Premenopausal women: endogenous estrogen may elicit a digoxin-like
effect and provoke ST-segment changes resulting in a false
positive exercise electrocardiogram.
In the premenopausal woman, angina and ischemia have been
shown to vary by the menstrual cycle. In the luteal/menstrual
phase, where estradiol levels are low, a greater prevalence of
ischemia and reduced time to ischemia onset has been noted.
Postmenopausal women: the prevalence of coronary disease is
increased resulting in a higher predictive accuracy.
Menopausal symptom therapy (previously called hormone
replacement therapy): these agents promote peripheral
vasoreactivity with evidence noting an increase in exercise time, a
decrease in myocardial ischemia in postmenopausal women with
coronary disease (note: there has been a decrease in the
prevalence of electrocardiographic (but not perfusion) ischemia.
) Functional capacity
There is a diminished ability to elicit ischemia if adequate heart rate
and estimated metabolic equivalents (METs) have not been
achieved. Women incapable of performing 5 METs on exercising
testing should be re-tested with pharmacologic stress imaging.
) Disease prevalence
In women with a lower prevalence of disease and a greater prevalence
of single-vessel disease, the overall predictive accuracy of stress
testing with or without imaging is diminished when compared to
a male population.
) Electrocardiographic changes
Resting ST-T-wave changes: the presence of significant resting ST-
T-wave changes on a 12-lead electrocardiogram diminishes the
accuracy of identifying peak exertional changes. Current
American College of Cardiology/American Heart Association
guidelines recommend cardiac imaging in women and men with
significant ST-T-wave changes on their resting
electrocardiogram.
Lower electrocardiogram voltage: population-based studies have noted
a lower QRS voltage that may affect the test’s diagnostic accuracyomen. METs  achieved metabolic equivalents during exercise testing;
mission computed tomography or dobutamine stress echocardiography.
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February 7, 2006:4S–20S Gender Differences, Symptom Evaluation, and Diagnostic Strategies73). Recent reports emphasize the importance of tracking heart
ate responses in the recovery phase of exercise. Deconditioning
ay manifest elevated sympathetic nervous system activity and a
elayed restoration of cardiac vagal tone post-stress (168–173),
eflected by persistently elevated heart rates post-exercise. By
ubtracting 2-min recovery from the peak heart rate value, a
ecrease of less then 44 beats is inversely related to all-cause
ortality in women (169). This measurement of heart rate
ecovery may be particularly important for deconditioned women
ho have a rapid heart rate increase within the first few minutes
f the onset of exercise that remains elevated during recovery.
tress-induced perfusion abnormality assessment. In the
ime course of the ischemic cascade, reductions in myocar-
ial perfusion occur earlier than either ECG or ventricular
all motion abnormalities and may provide a more precise
or sensitive) measure for estimating IHD risk. Although
any other techniques can be applied, myocardial perfusion
ingle-photon emission computed tomography (SPECT) is
nuclear-based technique that is most commonly used for
he evaluation of women presenting with chest pain symp-
oms (174). Generally, the literature supports the fact that
PECT imaging is highly sensitive for the detection of
AD in both women and men (174). The accuracy of
PECT techniques is diminished in women with a limited
xercise capacity and, for that reason, pharmacologic stress
esting (commonly performed with adenosine or dipyridam-
le) is recommended by the American College of Cardiol-
gy/American Heart Association and American Society of
uclear Cardiology guidelines (174–176). Diagnostic spec-
ficity, however, can be influenced by both breast tissue and
besity that can interfere with image quality and cause false
ositive test results, especially in the anterior and lateral
egions of the heart. For this reason, the higher energy
c-99m radioisotopes are preferred in women due to a
eduction in soft tissue attenuation artifacts (174–176).
rom the recent American Society of Nuclear Cardiology
tatement on women and based upon randomized trial
vidence, use of Tc-99m agents improves diagnostic speci-
city in women (174,175). In general, however, the inter-
retation of regional perfusion deficits is challenging in
omen as one must first exclude technical limitations with
ither attenuation correction or prone imaging techniques.
urther reductions in false positives (i.e., improvements in
iagnostic specificity) can be aided by integrating global or
egional left ventricular wall motion and function as well as
all thickness as a guide to discerning true positive reduc-
ions in regional myocardial perfusion. For example, a
tress-induced perfusion artifact may be called in the setting
f normal contraction and thickening of the left ventricle.
The improvements in image quality with Tc-99m-based
gents and computer capabilities (including attenuation
orrection) for SPECT imaging has resulted in dramatic
mprovements in diagnostic accuracy for women (Table 2).
s a result, large observational series have noted similar
bilities to risk stratify women and men with chest pain
ymptoms (174–182). From a multicenter registry of 3,402 oomen with stable chest pain symptoms when stratified by
he number of vascular territories with ischemia, three-year
urvival was similar and ranged from 98.5% to 85% for 0 to
coronary artery territories (181). Diabetic women, in
articular those requiring insulin treatment, have the worst
vent-free survival with inducible ischemia (177,182,183).
rom a summary meta-analysis, the relative risk of cardiac
eath or non-fatal myocardial infarction with a high-risk
erfusion scan was elevated 9.0-fold (95% CI 6.9 to 11.7)
nd was similar to recent prognostic evidence with stress
chocardiography (182). A revision of the recent consensus
tatement from the American Society of Nuclear Cardiol-
gy’s work-up algorithm for non-invasive imaging in
omen is depicted in Figure 5 (174).
For SPECT perfusion techniques, deficits are identified
ased upon differences in regional distribution of blood flow
hat is comparatively assessed (i.e., normalized) across the
yocardium. It is therefore possible that in the setting of global
oronary vascular dysfunction (endothelial or microvascular
ysfunction), the SPECT study could show no regional dif-
erences in the distribution of flow and appear normal. Addi-
ionally, global reductions in flow or impaired vasodilatory
esponses to stress may reflect balanced reduction in flow,
lthough this is more often noted in the setting of severe,
ultivessel CAD. Thus, the use of both positron emission
omography and magnetic resonance (MR) techniques may
rovide unique advantages over SPECT; however, this has yet
o be established in the published literature. An additional
hallenge with the use of nuclear imaging techniques is the fact
hat women have smaller hearts with the possibility that
maller myocardial areas of reduced perfusion may be missed as
result of limitations in spatial resolution with SPECT
ameras. Although these small abnormalities may not be
rognostically important (i.e., for major cardiac events), they
ay explain persistent chest pain syndromes in women, par-
icularly for those with non-obstructive CAD.
tress-induced wall motion abnormality assessment. As
all motion abnormalities appear after perfusion abnormal-
ties, evaluation of this marker has been associated with a
igher diagnostic specificity (104,142–144,146). Stress
chocardiography, the most commonly applied test for wall
otion assessment, has advantages due to its lower cost,
bsent radiation exposure, and ability to image both cardiac
tructures as well as ventricular function. Despite these
dvantages, echocardiographic techniques can also be sub-
ptimal in women due to obesity or lung disease limiting
coustic windows and reducing exercise tolerance. Use of
ntravenous contrast enhancement has been shown to im-
rove left ventricular opacification for those with an initially
uboptimal acoustic window. Women who are incapable of
aximal exercise are commonly referred to dobutamine (in
he U.S.) or dipyridamole (in Europe) pharmacologic stress
chocardiography (184). An important factor that affects the
cquisition of peak stress wall motion changes is the
xperience of both the sonographer and clinician to rapidly
btain multiple echocardiographic views at peak heart rates.
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Gender Differences, Symptom Evaluation, and Diagnostic Strategies February 7, 2006:4S–20Shus, similar to SPECT imaging, there are limitations to
he use of echocardiography in women that may challenge
he test’s interpretation.
Despite these limitations, the diagnostic accuracy data,
ased upon several decades of experience and nicely sum-
arized in a recent report from the Agency for Health-
elated Quality, reveal that exercise echocardiography is
ighly accurate at detecting CAD in women (i.e., Table 2,
ensitivity84% and specificity76%). Additionally, more
ecent evidence also supports the use of stress echocardio-
raphic techniques for the estimation of prognosis in
omen (44,146,185–187). In a recent report in 4,234
omen, the extent of ischemic wall motion abnormalities
as highly predictive of cardiac death (185). For women
ndergoing exercise echocardiography, five-year survival
anged from 99.4%, 97.6%, and 95% for those with no,
ingle, and multivessel ischemia, respectively (p  0.0001).
ignificantly higher cardiac death rates were noted for those
omen undergoing dobutamine stress echocardiography
ith annualized death rates ranging from 1% to 3% for
ero- to three-vessel ischemia (p  0.0001) (185).
ardiovascular MR assessment. Cardiovascular MR im-
ging may also provide unique clinical utility for the
valuation of subendocardial ischemia, improved precision
or the assessment of left ventricular function and mass, and
detailed anatomic evaluation of both the myocardium as
ell as the imaging the peripheral vasculature (188–194).
agnetic resonance spectroscopy can also detect alterations
igure 5. A revision of the recent consensus statement from the American
esting in women. The revision includes the application of ASNC’s guidelin
coronary artery disease; ECG  electrocardiogram; EF  ejection fracn myocardial metabolism with changes in high-energy shosphates (193,194). There are specific advantages to the
se of MR imaging that may lend itself to the evaluation of
omen including excellent soft tissue characterization and
ontrast, three-dimensionality, an absolute quantitation of
lood flow, and overall superior temporal and spatial reso-
ution to image vascular and myocardial abnormalities
188–194). Although not in common practice, MR tech-
iques have been applied for the evaluation of suspected
yocardial ischemia in female patients with chest pain
ymptoms and to lower risk cohorts (188–194). From one
ecent small series, MR perfusion was reported to be highly
ccurate to the detection of single-vessel obstructive CAD
191). Due to superior spatial resolution, MR delineates
ubendocardial perfusion (an initial manifestation of myo-
ardial ischemia) from epicardial perfusion and may provide
orollary evidence as to the etiology of chest pain symptoms
n women, particularly in the absence of obstructive CAD
189). Panting et al. (189) utilized this feature of MR
erfusion imaging to support the concept that subendocar-
ial ischemia may be responsible for chest pain in women
ith angina but without obstructive CAD. From this
eport, they demonstrated reduced subendocardial perfusion
n response to vasodilator stress using adenosine. Addition-
lly, 31P MR spectroscopy identifies alterations in high-
nergy phosphates (i.e., reduction in phosphocreatine/
denosine triphosphate [PCr/ATP] ratio) providing a
irect assessment of metabolic myocardial ischemia
193,194). A recent report noted worsening event-free
ety of Nuclear Cardiology’s (ASNC) work-up algorithm for non-invasive
ll cardiac imaging modalities. Adapted from Mieres JH, et al. (174). CAD
Ex  exercise; LV  left ventricular; METs  metabolic equivalents.Sociurvival (predominately chest pain hospitalizations) for
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February 7, 2006:4S–20S Gender Differences, Symptom Evaluation, and Diagnostic Strategieshose women with a reduced PCr/ATP ratio 20% and
on-obstructive coronary arteries. This recent prognostic
nding from the WISE study raises the significance of
he 31P MR evidence of myocardial ischemia as an
xplanation for the frequent hospitalization of women
ith non-obstructive coronary arteries who have persis-
ent and often refractory symptoms warranting hospital-
zation while consuming large amounts of healthcare
esources. Furthermore, evidence of metabolic ischemia
ffers an insight into the pathophysiology and potential
arget for the treatment of syndrome X, as testing and
reatment strategies are not currently defined (194).
hese results coincide with a similar report on cardiac
yndrome X noting that hsCRP values were in the
ntermediate range between healthy controls and those
ith CAD (195). Thus, this evidence from small patient
ohorts suggests that chest pain in the setting of non-
bstructive CAD, a prevalent condition, may be less
enign than previously considered (to be discussed in
reater detail in part II of this review). However, MR has
ts own limitations with a closed bore magnet causing
laustrophobia in certain patients.
ONCLUSIONS
n this review, we have synthesized a large body of evidence
n gender-related differences in cardiovascular epidemiol-
gy with notable differences in disease prevalence and
igure 6. Proposed paradigm for testing of asymptomatic and symptomatic
o 20% for intermediate Framingham risk scores and 20% for high Fra
agnetic resonance imaging; CT  computed tomography; ECG  elect
omputed tomography.ssociated clinical outcomes for women. Variability in the onset, relative risk, and the synergy of traditional and novel
isk factors creates a tremendous challenge to busy clinicians
ossibly resulting in suboptimal management and inequities
n access for women in today’s healthcare environment.
merging data suggest a unique risk profile in women
ncluding hypoestrogenemia coupled with the adverse ef-
ects of a protracted dysmetabolic state on promoting an
nflammatory milieu and/or vascular or metabolic alterations
hat may provoke both symptoms and ischemia in the
etting of non-obstructive CAD.
Additionally, for the growing proportion of women without
bstructive CAD, chest pain symptoms and functional limitations
ay be more related to metabolic alterations resulting in shifting
nergy substrates toward myocardial and peripheral glucose (an-
erobic) metabolism. Thus, traditional stress testing that is based
n demand ischemia often performs poorly to detect obstructive
AD in cohorts of women without a significant coronary stenosis.
he poor performance of cardiac imaging tests, such as stress
chocardiography and SPECT imaging, for the diagnosis of
bstructive CAD has been circumvented by the application of
hese techniques for risk assessment purposes. There is now
ubstantial evidence in large female cohorts that both stress
chocardiography and SPECT imaging techniques have a high
egree of accuracy for the estimation of near-term prognosis (i.e.,
wo- to five-year event-free survival) in women with chest pain
ymptoms. Furthermore, these data illustrate that there is an
pparent disconnect between obstructive disease burden and the
en including detection of subclinical and obstructive coronary disease. *6%
am risk scores. CHD  coronary heart disease; CMR  cardiovascular
iogram; MI  myocardial infarction; SPECT  single-photon emissionwom
minghverall ensuing risk of provocative ischemia in women. This
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Gender Differences, Symptom Evaluation, and Diagnostic Strategies February 7, 2006:4S–20Saradigm of risk assessment as a guide for test decision making
ay provide the key to identifying at-risk women. We need to
evise paradigms for testing in women that include the assessment
f asymptomatic and symptomatic women (Fig. 6). In part II, we
ill further examine gender differences in the extent and severity of
AD and its resultant impact on major adverse cardiac events.
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